EXTON, PA — Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating intratumoral tilsotolimod, Idera’s investigational Toll-like receptor 9 (TLR9) agonist, will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, to be held April 27-28, 2020, as part of a “Clinical Trial Poster Session.”
ILLUMINATE-206 is an ongoing phase 2, open-label, multicohort, multicenter study to test the safety and efficacy of intratumoral tilsotolimod in combination with Yervoy®* (ipilimumab) and Opdivo® (nivolumab) for the treatment of solid tumors. The trial initiated in September 2019 with the microsatellite stable colorectal cancer (MSS-CRC) cohort. A description of the trial in progress will be presented.
ILLUMINATE-101 was a phase 1b trial of intratumoral tilsotolimod monotherapy in patients with refractory solid tumors, which was completed in December 2019. Final results will be presented.
Hani M. Babiker, M.D., from the University of Arizona Cancer Center will present both studies. The abstract titles are as follows:
- Abstract # 10614: Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling in solid tumors
- Abstract # 10591: A phase 2 multicenter study to evaluate the efficacy of tilsotolimod in combination with nivolumab and ipilimumab for treatment of microsatellite-stable colorectal cancer (ILLUMINATE-206)
“We are very pleased that Dr. Babiker from the University of Arizona Cancer Center will present information from our studies investigating tilsotolimod in solid tumors,” stated Elizabeth Tarka, M.D., Idera’s Chief Medical Officer. “We continue to be excited about the broader potential of tilsotolimod beyond melanoma.”
The abstracts and video presentations will be available at 12:01 AM ET on Monday, April 27. Video presentations will be available for viewing on demand through the virtual meeting platform
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.